Novel biologic drug holds promise for individualized ovarian cancer treatment
Researchers have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. This would improve treatment and survival rates for some women.
"We have known that the protein HE4 is present in women who have ovarian cancer," said Richard G. Moore, MD, of Women and Infants Hospital of Rhode Island in Providence. He created the Risk of Ovarian Malignancy Algorithm (ROMA) to determine if a pelvic mass is cancerous based on the levels of HE4 and another protein. "What no one knew was why the protein is there or what activates it."
The WFCD2 gene produces a messenger RNA that encodes for the HE4 protein, not only imparting an aggressiveness to the tumor that enables it to grow quickly, but also conveying a resistance to chemotherapy drugs used to treat the tumor.
"It plays a part in allowing the cancer to grow without restriction," Moore said. "We have determined that HE4 plays a part in allowing ovarian cells to become cancer cells, giving them the ability to grow and resist chemo."
Once they identified the function of the protein, Moore's research team was able to design a biologic drug that can prevent the messenger RNA gene from creating HE4. The novel biologic has been tested in cell and animal models, and the results are that the cancer does not grow as aggressively and responds to chemotherapy.
"We would give this biologic, which has minimal side effects, to any patient we identify through a blood test as producing HE4," he said, adding that oncologists have recognized that women with high levels of HE4 do not respond to treatment and their survival rates are lower. "This would be an individualized treatment that could increase survival rates of some women with ovarian cancer."
Moore and his team will continue testing the biologic drug, preparing for clinical trials in humans. Their current study was published in Scientific Reports (2014; doi:10.1038/srep03574).